The SPP1-CD44 interaction is known to impede sustained T cell proliferation [57] and promote tumor progression in various cancers, including glioma [58], gastric cancer [59], prostate cancer [60], and pancreatic cancer [61]. Here, SPP1 is linked to prostate carcinoma.